AxSpA Podcast: The Efficacy and Safety of Ixekizumab & Tildrakizumab

Dr Sofia Ramiro, consultant rheumatologist and senior researcher at Zuyderland Medical Centre and Leiden University Medical Centre in the Netherlands, is joined by Professor Hideto Kameda, Professor of Internal Medicine at Toho University and Atul Deodhar, Professor of Medicine and Medical Director of Rheumatology Clinics in the Division of Arthritis & Rheumatic Diseases at Oregon Health & Science University in Portland, USA to discuss the Efficacy and Safety of Ixekizumab & Tildrakizumab.

In the first paper discussed, it describes the safety and efficacy of ixekizumab treatment in patients with r-axSpA and nr-axSpA for up to 156 weeks. The second study discussed goes on to assess the safety and efficacy of tildrakizumab in patients with active AS.

Discussing Rheumatology: September 2023

Join Prof Iain McInnes as he reviews two interesting papers , that retrospectively investigate the properties of JAK inhibitors.

In our first paper, Peter Taylor and his colleagues review the pharmacological differences between JAK inhibitors, and how these may affect safety and efficacy. In the second, Qige Wei and colleagues carried out a network meta-analysis of 14 RCTS to identify any associations between RA therapies and MACE or all-cause mortality.

To access detailed summary slides of the papers discussed, visit

August 2023

Author Interview: Sofia Ramiro

Professor Peter Nash from the Griffith University in Brisbane, is joined by Doctor Sofia Ramiro, a Consultant Rheumatologist and Senior Researcher at Leiden University Medical Centre to discuss her recent paper 'Do Fatty Lesions Explain the Effect of Inflammation on New Syndesmophytes in Patients with Radiographic Axial Spondyloarthritis? Results From the SIAS Cohort and ASSERT Trial'

Discussing Rheumatology: August 2023

Join Prof Iain McInnes as he reviews two interesting papers.

Our first paper today by Charles-Schoeman and colleagues compared paraoxonase activity in RA patients treated with tofacitinib, with a focus of PON1 genotypes. Furthermore, the relationship between PON1 genotypes and the risk of MACE and malignancy were also investigated.

In our second paper, Peter Taylor and colleagues evaluated the results of several baricitinib RCTs and real-world evidence studies.

AxSpA Podcast: Tofacitinib, Golimumab, and Fatigue

Join Professor Hideto Kameda, and Dr Sofia Ramiro as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the field of axSpA therapeutics, providing their own insights and experience into two very interesting publications. Our first paper aimed to use mediation modelling to determine whether tofacitinib improved fatigue symptoms directly or indirectly. Our second paper shows that IV-golimumab reduces fatigue symptoms in patients with ankylosing spondylitis.

July 2023

Discussing Rheumatology: July 2023

Join Prof Iain McInnes as he reviews two interesting papers.

Our first paper today by Roy Fleischmann and his colleagues compares the incidence of serious adverse events in RA patients with a higher risk of cardiovascular events and the overall RA population in a post-hoc study. They also compared the incidence rate of adverse events for upadacitinib, adalimumab and methotrexate, or methotrexate monotherapy.

In our second paper, Mohammed Khan and colleagues compared tofacitinib against methotrexate as first-line therapies against RA, with a focus on treatment remission.